Panel: Alternative funding models and capital structures for biotech

Traditional venture capital is growing more selective and early-stage biotech are sourcing other routes of funding to progress their pipelines. Explore how alternative funding models are evolving to support early-stage innovation, and what it takes to successfully navigate a more fragmented and competitive funding landscape.

• Why traditional VC is pulling back from early-stage CGT and what this means for company creation
• Beyond venture capital – the growing role of grants, venture philanthropy, angel investors, family offices and strategic partnerships in early-stage funding
• How founders can combine multiple capital sources to build a blended funding strategy